1. Home
  2. CXE vs SPRO Comparison

CXE vs SPRO Comparison

Compare CXE & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.82

Market Cap

117.9M

Sector

Finance

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXE
SPRO
Founded
1989
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.9M
124.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CXE
SPRO
Price
$3.82
$2.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
61.9K
337.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.36%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
$47,977,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$55.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.38
$0.51
52 Week High
$3.88
$3.09

Technical Indicators

Market Signals
Indicator
CXE
SPRO
Relative Strength Index (RSI) 57.21 46.81
Support Level $3.66 $2.15
Resistance Level N/A $2.44
Average True Range (ATR) 0.04 0.10
MACD -0.00 -0.01
Stochastic Oscillator 70.83 44.40

Price Performance

Historical Comparison
CXE
SPRO

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: